1. Home
  2. SEPN vs IGD Comparison

SEPN vs IGD Comparison

Compare SEPN & IGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SEPN
  • IGD
  • Stock Information
  • Founded
  • SEPN 2022
  • IGD N/A
  • Country
  • SEPN United States
  • IGD United States
  • Employees
  • SEPN N/A
  • IGD N/A
  • Industry
  • SEPN
  • IGD Trusts Except Educational Religious and Charitable
  • Sector
  • SEPN
  • IGD Finance
  • Exchange
  • SEPN NYSE
  • IGD Nasdaq
  • Market Cap
  • SEPN 453.2M
  • IGD 422.7M
  • IPO Year
  • SEPN 2024
  • IGD N/A
  • Fundamental
  • Price
  • SEPN $10.41
  • IGD $5.68
  • Analyst Decision
  • SEPN Buy
  • IGD
  • Analyst Count
  • SEPN 4
  • IGD 0
  • Target Price
  • SEPN $27.00
  • IGD N/A
  • AVG Volume (30 Days)
  • SEPN 559.2K
  • IGD 215.3K
  • Earning Date
  • SEPN 08-15-2025
  • IGD 01-01-0001
  • Dividend Yield
  • SEPN N/A
  • IGD 9.15%
  • EPS Growth
  • SEPN N/A
  • IGD N/A
  • EPS
  • SEPN N/A
  • IGD N/A
  • Revenue
  • SEPN $977,000.00
  • IGD N/A
  • Revenue This Year
  • SEPN N/A
  • IGD N/A
  • Revenue Next Year
  • SEPN $526.96
  • IGD N/A
  • P/E Ratio
  • SEPN N/A
  • IGD N/A
  • Revenue Growth
  • SEPN 108.76
  • IGD N/A
  • 52 Week Low
  • SEPN $4.17
  • IGD $4.60
  • 52 Week High
  • SEPN $28.99
  • IGD $5.26
  • Technical
  • Relative Strength Index (RSI)
  • SEPN N/A
  • IGD 49.25
  • Support Level
  • SEPN N/A
  • IGD $5.72
  • Resistance Level
  • SEPN N/A
  • IGD $5.79
  • Average True Range (ATR)
  • SEPN 0.00
  • IGD 0.04
  • MACD
  • SEPN 0.00
  • IGD -0.01
  • Stochastic Oscillator
  • SEPN 0.00
  • IGD 31.25

About SEPN SEPTERNA INC

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.

About IGD Voya Global Equity Dividend and Premium Opportunity Fund

Voya Global Equity Dividend and Premium Opportunity Fund are a United States-based diversified, closed-end Fund. The primary objective of the Fund is to seek to provide investors with a high level of income from a portfolio of common stocks with historically attractive dividend yields and premiums from call option writing. The secondary investment objective of the company is capital appreciation. Under normal market conditions, the Fund will invest at least 80% of its managed assets in a portfolio of common stocks of dividend-paying companies located throughout the world.

Share on Social Networks: